CHINA HEALTH GROUP INC. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號:08225) 二零二三年第一季度业绩公告 截至二零二三年三月三十一日止三個月 ...

Financial Performance - The Group recorded a consolidated revenue of approximately RMB 13,090,000 for the year ended 31 December 2022, representing an 84.34% decrease from approximately RMB 83,601,000 in 2021[21] - The Group reported a loss before taxation of approximately RMB 15,826,000 for 2022, compared to a profit before taxation of approximately RMB 42,521,000 in 2021[22] - The basic and diluted loss per share for 2022 was RMB 1.59 cents, compared to earnings per share of RMB 3.65 cents in 2021[22] - The Group's reserves available for distribution as of December 31, 2022, amounted to approximately RMB 18,775,000, down from approximately RMB 34,150,000 in 2021[87] - The Board does not recommend the payment of any dividend for the year ended December 31, 2022, consistent with the previous year[81] Assets and Liabilities - Total assets decreased to approximately RMB 178,625,000 in 2022 from RMB 194,325,000 in 2021, while total liabilities slightly decreased to RMB 36,742,000 from RMB 38,753,000[21] - The Group's net current assets were approximately RMB 140,484,000 as of 31 December 2022, down from RMB 154,022,000 in 2021[27] - The gearing ratio remained at 0% as of 31 December 2022, indicating no borrowings during the year[28] - As of December 31, 2022, the Group's total banking facilities amounted to nil, indicating no charge on assets[48] Operational Challenges and Strategies - The management faced significant challenges due to the COVID-19 pandemic and strict pharmaceutical market regulations but managed to maintain operations without large-scale layoffs[32] - The Group aims to strengthen its professional capacity building in response to the downward pressure in the domestic drug market[33] - The Group plans to raise further funds through bank loans, issuance of new shares, convertible notes, and new debts to support future development[29] Research and Development - The Group has established five major specialty brands focusing on brain science, allergies, and viruses, with a core strategy of building a R&D-based digital health care system[34] - The Group's big data platform for precision medicine enhances clinical research capabilities, aiming to replace traditional CSO models with digital clinical research[35] - The Group's "Research-based Therapy RWS-Therapy Model" and "Digital clinical research-based promotion D-CRCO model" redefine treatment and commercialization approaches in the healthcare sector[36] - The Group's Xien Brain Digital Clinical Research Center has participated in or organized over 60% of major national clinical studies in brain science[41] - The Group's "RWS Wanquan Center" aims to re-screen existing drugs using big data to discover optimal treatments for various diseases[42] - The Group has established digital medicine clinics in major cities, collaborating with top medical institutions to enhance healthcare services[43] Shareholder Information - As of December 31, 2022, the total number of shares held by the Chairman, GUO Xia, is 132,851,941, representing 13.35% of the total shares[92] - Winsland Agents Limited holds 349,368,873 shares, accounting for 35.10% of the total issued shares[94] - The total number of share options as at 31 December 2022 was 25,380,000 after accounting for lapsed and cancelled options[112] - The Share Option Scheme allows for the issuance of up to 10% of the total shares in issue on the adoption date, with 88,947,166 shares available for issuance under the scheme, representing approximately 8.94% of the total issued shares[106] Corporate Governance - The Company has complied with relevant laws and regulations, with no material breaches reported during the year[79] - The Company has complied with the Corporate Governance Code for the year ended 31 December 2022, with the exception of not having a Chief Executive Officer appointed[145] - The Company has established three committees: audit committee, nomination committee, and remuneration committee to oversee specific aspects of its affairs[165] - The Nomination Committee is responsible for nominating suitable candidates for the Board, ensuring a balance of skills, experience, and diversity[178] - The selection criteria for candidates include character, qualifications, experience, commitment, and independence as per GEM Listing Rules[179] Risk Management - The Group has implemented a sound risk management and internal control system, with ongoing reviews by the Board and Audit Committee[198] - An external independent consultant was engaged to review the internal control system of the Group during the year[198] - The risk management process includes identifying risks, assessing risk levels, and implementing risk management solutions[199] - The Group maintains a risk register to track identified risks and their responses, ensuring effective internal control procedures[200] Stakeholder Engagement - The Company maintains communication with stakeholders through various channels to understand their views and needs[74] - The Group's environmental and social strategies are monitored by dedicated managerial staff and the Board for overall ESG responsibility[73] Audit and Compliance - The Audit Committee reviewed the audited consolidated financial statements for the year ended 31 December 2021 and confirmed compliance with applicable accounting standards[167] - During the Year, the Audit Committee held four meetings with a 100% attendance rate[169] - The Remuneration Committee consists of one executive Director and three independent non-executive Directors, with a 100% attendance rate at meetings during the year[190][191] - The Board held two meetings during the year to review corporate governance policies, achieving a 100% attendance rate[197] - The Group's auditor confirmed that the continuing connected transactions for the year ended 31 December 2022 were in order[134]

Financial Performance - For the nine months ended September 30, 2022, the group recorded operating revenue of approximately RMB 33,316,000, a decrease of about 40.3% compared to the same period in 2021[5]. - The group reported a profit before tax of approximately RMB 19,259,000 for the nine months ended September 30, 2022, down approximately 38.0% from the same period in 2021[6]. - Basic earnings per share for the nine months ended September 30, 2022, were approximately RMB 1.64 cents, a decline of about 36.5% compared to the same period in 2021[7]. - The gross profit for the nine months ended September 30, 2022, was RMB 24,209,000, compared to RMB 44,064,000 for the same period in 2021, indicating a significant decrease[11]. - The total comprehensive income attributable to the equity holders of the company for the nine months ended September 30, 2022, was RMB 16,370,000, down from RMB 25,808,000 in the same period of 2021[11]. - The group's total revenue for the nine months ended September 30, 2022, was approximately RMB 33,316,000, representing a decrease of 40.3% compared to the same period in 2021[34]. - The pre-tax profit for the period was approximately RMB 19,259,000, down from RMB 31,059,000 in the same period last year[34]. - Net profit for the period was approximately RMB 16,370,000, compared to RMB 25,808,000 in the previous year[34]. - The group recorded a total revenue of RMB 3,017,000 for the three months ended September 30, 2022, a decline of 61% compared to the same period in 2021[20]. Dividends and Shareholder Returns - The board of directors recommended not to declare any dividend for the nine months ended September 30, 2022[8]. - The company has not declared any dividends for the nine months ended September 30, 2022, reflecting a cautious approach amid declining revenues[8]. - The board of directors did not recommend any dividend payment for the nine months ended September 30, 2022[27]. - The company has not engaged in any share buybacks or significant share transactions in the reported period, indicating a focus on maintaining capital[42]. Expenses and Costs - The group's administrative expenses for the nine months ended September 30, 2022, were RMB 19,290,000, compared to RMB 31,070,000 for the same period in 2021[11]. - Administrative expenses decreased by 62.12% year-on-year, totaling RMB 5,069,000 for the nine months ended September 30, 2022[21]. - The group’s financial costs for the nine months ended September 30, 2022, were RMB 31,000, a slight increase from RMB 11,000 in the same period of 2021[11]. Business Strategy and Market Focus - The group aims to become a comprehensive service provider under an internet framework in the healthcare sector, focusing on integrated pharmaceutical services[16]. - Revenue from post-listing medical clinical services, clinical research, medical liaison, and healthcare market services accounted for 100% of total revenue during the period[34]. - The company plans to enhance market promotion capabilities and expand market networks, focusing on value-added business models in the local market[35]. Corporate Governance and Structure - As of September 30, 2022, the company or its subsidiaries did not purchase, sell, or redeem any of the company's listed shares during the nine months[42]. - No directors or management shareholders held interests in any business that competes or may compete with the group's business as of the report date[43]. - As of September 30, 2022, the beneficial ownership of shares included 132,851,941 shares (13.35%) held by Guo Xia and 590,716,637 shares (59.34%) held by a controlled corporation[49]. - Winsland Agents Limited held 349,368,873 shares (35.10%) and Venturepharm Holdings Inc. held 149,432,583 shares (15.01%) as beneficial owners[54]. - The ownership structure indicates significant control by major shareholders, with over 59% of shares held by a single entity[49]. - The company has maintained sufficient public float as of the report date, ensuring compliance with public shareholding requirements[62]. - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[60]. - The company has not appointed a CEO, with daily operations managed by executive directors and senior management[58]. Risk Management - The majority of the group's transactions during the review period were denominated in RMB, with ongoing monitoring of foreign currency risks and appropriate hedging as needed[41]. - The company has a structured approach to monitoring and managing its foreign exchange risks, ensuring financial stability[41].

Financial Performance - For the six months ended June 30, 2022, the group recorded revenue of approximately RMB 30,299,000, a decrease of about 37.00% compared to RMB 48,093,000 for the same period in 2021[4] - The group reported a profit before tax of approximately RMB 19,117,000, down approximately 31.67% from RMB 27,977,000 in the same period of 2021[5] - Basic earnings per share for the six months ended June 30, 2022, were approximately RMB 1.63 cents, a decrease of about 30.04% from RMB 2.33 cents in the same period of 2021[5] - The net profit for the six months ended June 30, 2022, was RMB 16,249,000, compared to RMB 23,188,000 for the same period in 2021, representing a decrease of approximately 30%[28] - The income tax expense for the six months ended June 30, 2022, was RMB 2,867,000, compared to RMB 4,789,000 for the same period in 2021[30] Dividends - The board of directors recommended not to declare any dividend for the six months ended June 30, 2022[6] - The company did not recommend any dividend payment for the period, consistent with the previous year[31] - The board does not recommend the distribution of dividends for the six months ended June 30, 2022, consistent with the previous year[57] Cash Flow and Assets - The net cash generated from operating activities was RMB 716,000, compared to a net cash outflow of RMB 2,344,000 in the same period of 2021[16] - Total assets less current liabilities amounted to RMB 171,821,000 as of June 30, 2022, compared to RMB 155,572,000 as of December 31, 2021[14] - The group’s cash and cash equivalents decreased to RMB 7,086,000 from RMB 11,364,000 at the beginning of the period[16] - Trade receivables increased to RMB 142,759,000 as of June 30, 2022, from RMB 128,513,000 as of December 31, 2021[14] - As of June 30, 2022, the group's net current assets and net assets were approximately RMB 170,380,000 and RMB 171,821,000, respectively, compared to RMB 154,022,000 and RMB 155,572,000 as of December 31, 2021[55] Expenses - The group’s administrative expenses for the six months ended June 30, 2022, were RMB 821,000, down from RMB 5,853,000 in the same period of 2021[12] - The total administrative expenses and employee costs for the current period were approximately RMB 3,646,000, significantly lower than RMB 10,617,000 in the same period last year[54] Business Operations - The company is focused on providing integrated pharmaceutical services in China, including clinical research and post-market surveillance[20] - The company aims to become a comprehensive service provider under an internet framework in the healthcare sector[20] - The company established a biobanking laboratory to support clinical research, particularly for antiviral drug studies[46] - The company launched two new business models: RWS-Therapy and D-CRCO, aimed at redefining research-based treatment and commercialization in the digital healthcare era[47] - The company has formed partnerships with top medical institutions in cities like Beijing, Shanghai, and Guangzhou to enhance its digital healthcare services[48] Share Options and Governance - The stock option plan was approved on June 30, 2015, with a validity of 10 years[93] - The maximum number of shares available for subscription under the stock option plan is limited to 30% of the issued shares[100] - The total number of shares available for issuance under the share option plan is 78,087,166 shares, accounting for 7.85% of the total issued shares as of the interim report date[103] - The company has not granted, exercised, canceled, or allowed any other share options to lapse during the reporting period, aside from those mentioned[114] - The company has not appointed a CEO, and daily management is handled by executive directors and senior management[118] - The company complied with the corporate governance code during the reporting period, with exceptions noted regarding the separation of roles between the chairman and CEO[118] Market and Risk Management - The group closely monitors foreign currency risks and will hedge as necessary, with most transactions denominated in RMB[68] - The group continues to enhance its market promotion capabilities and expand its market network, focusing on value chain products in the local market[56] Employee Information - The total number of employees decreased from 50 as of December 31, 2021, to 44 as of June 30, 2022, with total employee and director remuneration approximately RMB 2,825,000, down from RMB 4,764,000 in the previous year[76]

Financial Performance - The Group achieved a turnover of RMB14,151,000 for the Period, representing a decrease of 46.04% from RMB26,226,000 compared to the corresponding period of 2021[25]. - The Group achieved profit before taxation of RMB8,465,000 for the Period, representing a decrease of 44.68% from RMB15,303,000 compared to the corresponding period of 2021[25]. - Basic and diluted earnings per share are RMB0.73 cents for the Period, representing a decrease of 45.11% from RMB1.33 cents compared to the corresponding period of 2021[26]. - The Group's unaudited net profit for the Period is approximately RMB7,289,000, down from RMB13,184,000 in 2021[16]. - For the three months ended 31 March 2022, the company reported a net profit of approximately RMB 7,289,000, a decrease of 44.8% compared to RMB 13,184,000 for the same period in 2021[32]. - Gross profit for the period was RMB 10,598,000, representing a decline of 46.2% from RMB 19,670,000 in the prior year[38]. - Profit from operations was RMB 8,449,000, down 44.5% from RMB 15,317,000 in the previous year[38]. - The Group recorded a turnover of RMB 14,151,000 for the three months ended 31 March 2022, representing a decrease of 46.04% from RMB 26,226,000 in the corresponding period of last year[118]. - Net profit for the period was approximately RMB 7,289,000, down 44.68% from RMB 13,183,000 in the same period of 2021[120]. Taxation and Dividends - No provision for Hong Kong Profits Tax has been made as the Group had no estimated assessable profits for the Period (2021: Nil)[19]. - The applicable income tax rate for PRC Enterprise Income Tax ranges from 9% to 25% as at 31 March 2022[20]. - The Board does not recommend the payment of any dividend for the three months ended 31 March 2022 (for the three months ended 31 March 2021: Nil)[22]. - The applicable income tax rate for the company and its subsidiaries ranges from 9% to 25% as of 31 March 2022, with some subsidiaries benefiting from a preferential tax rate of 9%[35]. - The company had no estimated assessable profits for Hong Kong Profits Tax for the period, similar to the previous year[34]. - The Group did not recommend any dividend payment for the three months ended 31 March 2022, consistent with the previous year[142]. Administrative Expenses - Administrative expenses for the quarter were RMB 2,197,000, a reduction of 50.3% compared to RMB 4,418,000 in the same period last year[38]. - Total consolidated administrative expenses and staff costs for the period were approximately RMB 2,197,000, compared to approximately RMB 4,418,000 in the previous year[119]. - Administrative expenses decreased by 50.27% compared to the corresponding period of 2021, amounting to RMB4,418,000[70]. Share Information - The weighted average number of ordinary shares for the Company for the Quarter is 995,351,660 shares[16]. - Basic earnings per share for the quarter were 0.73 cents, down from 1.33 cents in the same quarter of 2021[38]. - Basic earnings per share for the quarter was calculated based on a weighted average of 995,351,660 ordinary shares, with no adjustments made for dilution effects[71]. - Basic earnings per share for the quarter was calculated by dividing the net profit of approximately RMB 7,289,000 by the weighted average number of 995,351,660 ordinary shares[109]. Corporate Governance - The Company has complied with the Corporate Governance Code, except for the lack of a separate CEO, as the position has not yet been filled[191]. - The company emphasizes the quality, transparency, and accountability of its Board, although the roles of Chairman and CEO have not been separated due to the absence of a CEO appointment[192]. - The Audit Committee, consisting of three independent non-executive Directors, reviewed the unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[194]. Business Strategy and Operations - The Group has launched a value-added business model focusing on treatment products across the entire value chain, with sub-brands including Xienwanquan and Baimin Wanquan[121]. - The Group's "RWS Wanquan center" aims to re-screen existing drugs through real clinical research to find optimal treatments[99]. - The Group has established a biological sample testing laboratory to support clinical research, particularly for antiviral drugs[99]. - The Group is investing in enhancing its market promotion ability and expanding its market network in response to changes in the business model of Chinese pharmaceutical enterprises[121]. Shareholder Information - Winsland Agents Limited beneficially owns 349,368,873 shares, representing approximately 35.10% of the total issued shares of the Company[186]. - Bright Excel Assets Limited holds 91,915,181 shares, accounting for about 9.23% of the total issued shares[186]. - Venturepharm Holdings Inc. beneficially owns 149,432,583 shares, which is approximately 15.01% of the total issued shares[186]. - As of March 31, 2022, no other individuals were recorded as having interests or short positions in the shares of the Company[188]. - The Company has not been notified of any interests or short positions of the Directors and chief executive in the shares as of March 31, 2022[180]. Compliance and Reporting - These condensed consolidated financial statements were approved by the Board on 6 May 2022[24]. - The consolidated financial statements were approved by the board on 6 May 2022[87]. - The company has adopted a code of conduct for securities transactions by Directors, complying with the standards set out in Rules 5.48 to 5.67 of the GEM Listing Rules[193]. - The company has not yet applied the new Hong Kong Financial Reporting Standards that have been issued but not yet effective[55].

Trade Receivables - The company has trade receivables totaling RMB 44 million from four major clients, with aging of 180 days [3]. - The audit opinion raised concerns about the recoverability of trade receivables, leading to a qualified opinion due to insufficient audit evidence [5]. - Management believes that the audit qualification will not adversely affect the company's financial position or operations [6]. - The company plans to establish repayment agreements with clients by June 2022, outlining payment timelines and amounts [9]. - If receivables are not collected by October 2022, the company reserves the right to take legal action for collection [9]. - Management has communicated with clients to negotiate repayment plans and has already recovered some receivables [6]. - The company emphasizes the importance of maintaining close communication with clients regarding their operational status and willingness to repay [9]. Audit Opinion - The audit committee reviewed the qualified opinion and agreed with management's assessment regarding the risks of uncollectible receivables [8]. - The audit committee believes that the qualified opinion will not negatively impact the company's normal operations [8]. - The company expects to remove the audit qualification from its financial statements by the end of 2022 [9].

Financial Performance - For the nine months ended September 30, 2021, the group recorded revenue of approximately RMB 55,829,000, an increase of about 8.5% compared to the same period in 2020[5]. - For the same period, the group reported a profit before tax of approximately RMB 31,059,000, a decrease of about 16.1% compared to the prior year[6]. - Basic earnings per share for the nine months were approximately RMB 2.59 cents, down about 21.5% from the same period in 2020[7]. - The gross profit for the nine months was approximately RMB 44,064,000, compared to RMB 38,622,000 in the same period last year[11]. - The total comprehensive income for the nine months was RMB 25,808,000, compared to RMB 32,799,000 in the same period last year[11]. - Total revenue for the period increased by 8.5% compared to the same period in 2020, with total revenue for the three months ended September 30, 2021, decreasing by 18.00% compared to the same period in 2020[20]. - Basic earnings per share were approximately RMB 25,808,000, compared to RMB 32,799,000 for the same period in 2020, with a weighted average number of ordinary shares of approximately 995,351,660[23]. - The group achieved a pre-tax profit of approximately RMB 31,059,000, down from RMB 37,023,000 in the same period last year, with net profit approximately RMB 25,808,000 compared to RMB 32,799,000 last year, primarily due to the sale of three wholly-owned subsidiaries which generated a transfer gain of RMB 10,224,000 last year[34]. Dividends - The board of directors proposed not to declare any dividend for the nine months ended September 30, 2021[8]. - The company has not recommended any dividend payments for the period[27]. - The board does not recommend the distribution of dividends for the nine months ended September 30, 2021, consistent with the previous year[36]. Operating Expenses - The operating expenses for the nine months were RMB 31,070,000, down from RMB 37,061,000 in the previous year[11]. - Administrative expenses rose by 10.86% compared to the same period in 2020, amounting to RMB 2,728,000 for the three months ended September 30, 2021[21]. Business Strategy and Development - The group aims to become a comprehensive service provider under an internet architecture in the healthcare sector[16]. - The company has established a biobank testing laboratory to support clinical research, particularly for antiviral drug studies[29]. - The company launched two new business models: "RWS-Therapy" and "D-CRCO," aimed at redefining research-based treatment and commercialization through big data[30]. - The company has formed partnerships with top medical institutions in cities like Beijing, Shanghai, and Guangzhou to enhance digital healthcare services[30]. - The company is exploring a comprehensive digital healthcare service model that integrates research, rehabilitation, and medical tourism[31]. - The group is enhancing its marketing capabilities and expanding its market network, focusing on a value chain business model in the local market with its sub-brands[35]. - The board will review and evaluate potential projects or investments to enhance business performance and shareholder returns[35]. Financial Position and Investments - The group has not made any significant investments during the reporting period, similar to the situation as of December 31, 2020[37]. - As of September 30, 2021, the group had no unrecorded contingent liabilities, maintaining the same status as of December 31, 2020[38]. - The company has not disclosed any significant future investment or capital asset plans beyond what has been reported[39]. Shareholding Structure - Winsland Agents Limited holds 349,368,873 shares, representing 35.10% of the company's equity[55]. - Venturepharm Holdings Inc. has a beneficial ownership of 149,432,583 shares, accounting for 15.01% of the equity[55]. - Bright Excel Assets Limited, a wholly-owned subsidiary of Venturepharm Holdings Inc., holds 91,915,181 shares, which is 9.23% of the equity[57]. - The company has a controlled corporation interest of 241,347,764 shares, which is 24.25% of the equity[55]. Governance and Compliance - The company has not appointed a CEO, with daily management handled by executive directors and senior management[60]. - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited consolidated results for the period[62]. - The company maintains sufficient public float as of the report date[64]. - The company has complied with the GEM Listing Rules regarding securities trading standards during the reporting period[61]. - The board emphasizes high-quality governance and transparency to shareholders[60]. Miscellaneous - The group has not recognized any revenue from contract clinical research services during the period[20]. - There were no purchases, sales, or redemptions of the company's listed shares by the company or any of its subsidiaries during the nine months ended September 30, 2021[42]. - The report was published on November 11, 2021, and will be available on the GEM website for seven days[66].

Financial Performance - For the six months ended June 30, 2021, the group recorded revenue of approximately RMB 48,093,000, an increase of about 14.44% compared to the same period in 2020[4] - The group reported a profit before tax of approximately RMB 27,977,000 for the six months ended June 30, 2021, representing an increase of approximately 9.56% year-on-year[5] - Basic earnings per share for the six months ended June 30, 2021, were approximately RMB 2.33 cents, up about 4.95% from the same period in 2020[6] - The group’s net profit for the six months ended June 30, 2021, was RMB 23,188,000, compared to RMB 22,047,000 for the same period in 2020[10] - The total revenue for the six months ended June 30, 2021, increased by 14.44% compared to the same period in 2020, with PMS revenue growing approximately 16.80%[24] - The net profit attributable to the owners of the company for the period was approximately RMB 23,188,000, compared to RMB 22,047,000 in 2020[27] Assets and Liabilities - The group’s total assets less current liabilities as of June 30, 2021, amounted to RMB 142,435,000, compared to RMB 118,675,000 as of December 31, 2020[12] - The group’s cash and cash equivalents at the end of the period were RMB 11,582,000, down from RMB 16,193,000 at the beginning of the period[14] - The net cash used in operating activities for the six months ended June 30, 2021, was RMB (2,344,000), compared to RMB 3,113,000 for the same period in 2020[14] - Trade receivables increased to RMB 116,367,000 as of June 30, 2021, from RMB 86,056,000 as of December 31, 2020[12] - As of June 30, 2021, the group's net current assets were approximately RMB 140,802,000, an increase from RMB 116,924,000 as of December 31, 2020[51] - The group had no borrowings as of June 30, 2021, compared to secured bank borrowings of approximately RMB 1,500,000 as of December 31, 2020[51] Expenses and Costs - Administrative expenses rose by 123.40% compared to the same period in 2020, amounting to RMB (5,853,000) for the six months ended June 30, 2021[25] - The total administrative and employee costs for the period amounted to approximately RMB 10,617,000, up from RMB 7,384,000 in the previous year[50] - The income tax expense for the period was RMB 4,789,000, compared to RMB 3,489,000 in 2020[30] Dividends - The board of directors recommended not to declare any dividend for the six months ended June 30, 2021[7] - The company did not recommend any dividend payment for the period, consistent with the previous year[31] - No dividends were recommended for the six months ended June 30, 2021[53] Employee Information - The group had a total of 85 employees as of June 30, 2021, an increase from 82 employees at the end of 2020[73] - Employee compensation, including salaries and bonuses, amounted to approximately RMB 4,764,000 for the period, consistent with the previous year[73] Corporate Governance - The company adhered to the corporate governance practices as per the GEM Listing Rules, with a noted deviation regarding the separation of the roles of Chairman and CEO[110] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[112] - As of the report date, the company maintained sufficient public float as per the information available to the board[114] - The company’s board consists of two executive directors and three independent non-executive directors as of the report date[115] Stock Options - The company has a stock option plan in place, granting options to qualified participants[74] - The stock option plan aims to incentivize qualified participants for their contributions to the group's long-term development[91] - The total number of stock options granted during the period was 14,650,000, with a remaining balance of 25,500,000 as of June 30, 2021[105] - The exercise price for the stock options granted in March 2021 was HKD 0.504, with a total of 5,070,000 options granted during this period[105] - The maximum number of shares available for subscription under the stock option plan is 78,087,166 shares, representing 7.85% of the total issued shares as of the interim report date[98] - The maximum number of shares that can be issued to each eligible participant in any 12-month period cannot exceed 1% of the issued shares without shareholder approval[97] Future Plans - The group plans to enhance market promotion capabilities and expand market networks, focusing on a full value chain business model in the local market[52] - The group has established a digital medical service ecosystem, integrating research to rehabilitation[46] Risk Management - The group closely monitors foreign currency risks, with most transactions denominated in RMB, and will hedge as necessary[66] - The board continues to follow a prudent policy to manage cash and maintain strong liquidity to seize future growth opportunities[67] Other Information - There were no significant investments or acquisitions during the period[55][57] - There were no significant subsequent events after June 30, 2021, up to the report date[69] - The company did not engage in any share buybacks, sales, or redemptions during the reporting period[75] - The company has not granted, exercised, canceled, or allowed any other stock options to expire during the reporting period[108]

Financial Performance - For the three months ended March 31, 2021, the group recorded operating revenue of RMB 26,226,000, an increase of 21.58% compared to RMB 21,571,000 for the same period in 2020[6][39] - The group achieved a profit before tax of RMB 15,304,000, which represents a 27.25% increase from RMB 12,027,000 in the same period of 2020[7][20] - Basic and diluted earnings per share for the period were RMB 1.33 cents, up 25.5% from RMB 1.06 cents in the same period of 2020[7][27] - The group’s gross profit for the quarter was RMB 19,671,000, compared to RMB 16,426,000 in the same period of 2020[13] - The group’s total comprehensive income for the period was RMB 13,184,000, compared to RMB 10,573,000 in the same period of 2020[22] - The group’s operating profit for the quarter was RMB 15,318,000, compared to RMB 12,045,000 in the same period of 2020[16] - The net profit for the current period was RMB 13,184,000, up 24.83% from RMB 10,573,000 in the same period last year[41][55] Revenue Sources - The group reported related party revenue of RMB 8,019,000, accounting for approximately 31% of total revenue for the quarter[39] - The company reported related party revenue of RMB 8,019,000, accounting for approximately 31% of total revenue[55] Expenses - Administrative expenses for the quarter were RMB 4,418,000, slightly increasing from RMB 4,400,000 in the same period of 2020[15] - The administrative expenses for the current period were RMB 4,418,000, reflecting a slight increase of 0.41% from RMB 4,400,000 in the previous year[5] Dividend Policy - The board of directors recommended not to declare any dividend for the three months ended March 31, 2021[8] - The company did not recommend any dividend payment for the current quarter, consistent with the previous year[49][57] Corporate Governance - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited first-quarter results for the period ending March 31, 2021[78] - The company emphasizes the importance of corporate governance and has adopted a code of conduct for securities transactions by directors[76] - The board of directors includes two executive directors, Mr. Guo Xia (Chairman) and Dr. Song Xuemei, one non-executive director, Mr. Su Yi, and three independent non-executive directors, Mr. Qiu Rui, Dr. Ni Binhui, and Mr. Zhen Ling[81] - The announcement date is May 13, 2021, indicating the company's ongoing commitment to transparency and governance[81] Strategic Initiatives - The company has established a biobank testing laboratory to support clinical research, particularly for antiviral drug studies[52] - The company is investing in enhancing market promotion capabilities and expanding market networks, focusing on a full-value chain business model in the local market[56] - The company has developed two new business models: RWS-Therapy and D-CRCO, aimed at redefining research-based treatment and commercialization[52] - Future strategies may include the development of new products and technologies to meet evolving market demands[81] - The company aims to leverage strategic partnerships and potential acquisitions to accelerate growth and innovation[81] Shareholder Information - As of March 31, 2021, Winsland Agents Limited holds approximately 35.10% of the company's issued shares, totaling 349,368,873 shares[73] - The company has issued a total of 590,716,637 shares held by major shareholder Guo Xia, representing 59.35% of the total issued shares[67] - The company has granted a total of 250,000 stock options at an exercise price of HKD 0.45 per share, with a one-year lock-up period[69] - Guo Xia is deemed to have interests in 91,915,181 shares held by Bright Excel Assets Limited, a wholly-owned subsidiary of Venturepharm Holdings Inc[68] - The company has a total of 132,851,941 shares held by Guo Xia, which includes 114,701,941 shares directly owned[67] - The company has granted 9,150,000 stock options in 2015 and 9,000,000 stock options in 2021, with varying percentages of exercisability over the years[71] - The company has not reported any other individuals holding interests or short positions in its shares as of March 31, 2021[74] Operational Focus - The company is focused on enhancing its operational efficiency and expanding its market presence in the healthcare sector[81] - Continuous improvement in service delivery and patient care remains a top priority for the organization[81] - User data and customer engagement metrics are expected to be key performance indicators in future reports[81] - The company is committed to maintaining a strong financial position while exploring new market opportunities[81] - The board emphasizes the importance of adapting to market trends and consumer needs in the healthcare industry[81] - The company plans to provide updated performance guidance in upcoming financial disclosures[81]

CHINA HEALTH GROUP INC. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 二零二零年第三季度報告 截至二零二零年九月三十日止九個月 二零二零年第三季度報告 截至二零二零年九月三十日止九個月 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM 之定位，乃為相比起其他在聯交所上市之公司帶有較高投資風險之公司提供一個上市之市 場。有意投資之人士應瞭解投資於該等公司之潛在風險，並應經過審慎周詳之考慮後方作出投資決 定。GEM 之高風險及其他特色表示 GEM 較適合專業及其他經驗豐富投資者。 由於 GEM 上市公司之新興性質，在 GEM 買賣之證券可能會較於主機板買賣之證券承受較大之市 場波動風險，同時無法保證在 GEM 買賣之證券會有高流通量之市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失 承擔任何責任。 本報告乃遵照聯交所GEM證券上市規則之規定而提供有關中國醫療集團有限公司 ...